Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Breast cancer research and treatment·2013
Same author

Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status.

The oncologist·2010
Same author

Trastuzumab cardio-oncology: lessons learned.

Clinical journal of oncology nursing·2010
Same author

Adjuvant trastuzumab for HER2-positive early breast cancer.

Clinical journal of oncology nursing·2010
Same author

Trastuzumab.

Cancer treatment and research·2009
Same author

Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population.

Mayo Clinic proceedings·2009
Same journal

How Can Oncology Nurses Learn to See Beyond the Numbers?

Clinical journal of oncology nursing·2026
Same journal

Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey.

Clinical journal of oncology nursing·2026
Same journal

The Role of Oncology Nurses in National Breast and Cervical Cancer Screening Programs.

Clinical journal of oncology nursing·2026
Same journal

Technology-Assisted Nutrition Education Program for Patients With Cancer Undergoing Gastrectomy: A Quasi-Experimental Study.

Clinical journal of oncology nursing·2026
Same journal

The Hidden Biology of Life Experience: Using SEMOARS + GEM and Precision Health for Psychoneurologic Symptoms in Hematologic Malignancies.

Clinical journal of oncology nursing·2026
Same journal

GLP-1 Medications in Oncology Nursing Practice.

Clinical journal of oncology nursing·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Lapatinib side-effect management.

Cynthia Frankel1, Frances M Palmieri

  • 1Memorial Healthcare System, Hollywood, FL, USA. cfrankel@mhs.net

Clinical Journal of Oncology Nursing
|March 31, 2010
PubMed
Summary
This summary is machine-generated.

Lapatinib treatment can cause diarrhea and skin issues. Proactive management and dose adjustments are key for patients to continue therapy and maintain quality of life.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jun 14, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER2.
  • Diarrhea and dermatologic adverse events are common side effects of lapatinib therapy.

Purpose of the Study:

  • To review data on diarrhea and dermatologic adverse events in lapatinib-treated patients.
  • To summarize the role of oncology nurses in managing these adverse events.

Main Methods:

  • Review of existing data on lapatinib-induced adverse events.
  • Summary of management strategies including prevention, surveillance, treatment, and dose reduction.

Main Results:

  • Diarrhea severity varies, especially when combined with other agents.
  • Most dermatologic events are mild to moderate, but some require intervention.

Conclusions:

  • Proactive management of diarrhea and dermatologic adverse events is crucial for lapatinib therapy.
  • Oncology nurses play a vital role in patient education and management of these side effects.